HG6-64-1 inhibits the growth of DLBCL xenograft tumors and prolongs the survival of tumor-bearing mice. Mice bearing subcutaneous OCI-LY-19 xenograft tumors were treated with injections of HG6-64-1, R-CHOP, or PBS. Tumor volume (area in cubic millimeters) is depicted in mice treated with intratumoral injections of HG-6-64-1 (A) or intraperitoneal injections of HG6-64-1, intravenous R-CHOP with orally administered prednisone as described,²⁶  or PBS (B). Overall survival of the mice is shown in (C-D). Similar results to those shown in (A-D) were observed in one additional independent experiment. The P value for survival of mice given R-CHOP treatment compared with control was P = .0082; HG6-64-1 compared with control was P = .0034, and HG6-64-1 compared with R-CHOP was P = .02. IT, intratumoral administration; IP, intraperitoneal administration; IV + oral, intravenous administration alongside oral prednisone.